Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6118386 | 0.75 | ALDH1A1 (0.41) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL4775813 | 0.73 | LOXL2 (0.42) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL7984828 | 0.71 | TAS1R3 (0.41) | TAS1R3TAS1R1DHODHPRNPRXFP1 | |
| SCHEMBL586189 | 0.70 | PRNP (0.49) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL12359739 | 0.70 | PRNP (0.45) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL30693720 | 0.70 | PRNP (0.49) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL11199425 | 0.70 | TAS1R3 (0.45) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL1253465 | 0.70 | TAS1R3 (0.47) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 | |
| SCHEMBL8701086 | 0.70 | MAOB (0.50) | LMNAALDH1A1HPGD | |
| SCHEMBL586085 | 0.69 | GPR3 (0.44) | TAS1R3TAS1R1PRNPRXFP1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2054422-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2009-05-06 | — | — | EP | disclosed |
| EP-1973902-A2 | 3-HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | Affinium Pharmaceuticals, Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008009122-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | TAS1R3 3153/4885TAS1R1 3637/4885DHODH 1140/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | TAS1R3 1343/4885TAS1R1 1189/4885DHODH 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.